Literature DB >> 20532122

Pramipexole and compulsive masturbation.

Randy A Sansone1, Mark Ferlan.   

Abstract

OBJECTIVE: Exploration of a possible relationship between pramipexole and compulsive masturbation.
METHODS: We present a case report.
RESULTS: Given the temporal overlap between pramipexole prescription and its discontinuation, and the onset and cessation of the patient's hypersexual behavior, there appears to be a strong likelihood of association.
CONCLUSIONS: Like other dopamine agonists, pramipexole may precipitate compulsive behaviors, including hypersexual behavior in the form of compulsive masturbation.

Entities:  

Keywords:  adverse effects; compulsive sexual behavior; dopamine agonists; hypersexual behavior; masturbation

Year:  2007        PMID: 20532122      PMCID: PMC2880944     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  18 in total

1.  Repetition, repetition, and repetition: compulsive and punding behaviors in Parkinson's disease.

Authors:  Valerie Voon
Journal:  Mov Disord       Date:  2004-04       Impact factor: 10.338

2.  Problematic gambling on dopamine agonists: Not such a rarity.

Authors:  Katherine A Grosset; Graeme Macphee; Guru Pal; David Stewart; Andrew Watt; Jim Davie; D G Grosset
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

3.  Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease.

Authors:  A H Evans; A D Lawrence; J Potts; S Appel; A J Lees
Journal:  Neurology       Date:  2005-11-22       Impact factor: 9.910

4.  Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.

Authors:  Michael A Shapiro; Yu Ling Chang; Sarah K Munson; Michael S Okun; Hubert H Fernandez
Journal:  Parkinsonism Relat Disord       Date:  2006-05-26       Impact factor: 4.891

5.  Prevalence of pathological gambling in patients with Parkinson's disease.

Authors:  Maurizio Avanzi; Mario Baratti; Silvia Cabrini; Elena Uber; Gianni Brighetti; Flavio Bonfà
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

6.  Pathological gambling caused by drugs used to treat Parkinson disease.

Authors:  M Leann Dodd; Kevin J Klos; James H Bower; Yonas E Geda; Keith A Josephs; J Eric Ahlskog
Journal:  Arch Neurol       Date:  2005-07-11

7.  Association of dopamine agonist use with impulse control disorders in Parkinson disease.

Authors:  Daniel Weintraub; Andrew D Siderowf; Marc N Potenza; Joseph Goveas; Knashawn H Morales; John E Duda; Paul J Moberg; Matthew B Stern
Journal:  Arch Neurol       Date:  2006-07

8.  [Reversible pathological gambling under treatment with pramipexole].

Authors:  K Spengos; E Grips; G Karachalios; G Tsivgoulis; G Papadimitriou
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

9.  Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease.

Authors:  Valerie Voon; Teri Thomsen; Janis M Miyasaki; Minella de Souza; Ariel Shafro; Susan H Fox; Sarah Duff-Canning; Anthony E Lang; Mateusz Zurowski
Journal:  Arch Neurol       Date:  2007-02

10.  Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

Authors:  Kevin J Klos; James H Bower; Keith A Josephs; Joseph Y Matsumoto; J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2005-09       Impact factor: 4.891

View more
  3 in total

1.  A case of sleep masturbation related to dopamine agonist therapy.

Authors:  Robert J Sawyer; Randy A Sansone
Journal:  Prim Care Companion CNS Disord       Date:  2012-05-10

2.  Spontaneous Ejaculations Associated with Aripiprazole.

Authors:  Oğuzhan Eğilmez; Mustafa Çelik; Aysun Kalenderoğlu
Journal:  Noro Psikiyatr Ars       Date:  2016-03-01       Impact factor: 1.339

3.  Two cases of hypersexuality probably associated with aripiprazole.

Authors:  Eunjin Cheon; Bon-Hoon Koo; Sang Soo Seo; Jun-Yeob Lee
Journal:  Psychiatry Investig       Date:  2013-05-30       Impact factor: 2.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.